Generic
-
{
- All
- News
- Videos
- Web Stories
-
India Supplies 30% Of Global Generic Drugs: What You Should Know
India supplies nearly thirty percent of the worlds generic medicines and aims to boost domestic use to reduce patients out-of-pocket costs.
-
Jan Aushadhi Scheme Saves Citizens Rs 45,000 Crore On Medicines In 12 Years: Govt
A total of 20,149 Jan Aushadhi Kendras have been opened nationwide and estimated savings of about Rs 45,000 crore have accrued to citizens from the Pradhan Mantri Bhartiya Janaushadhi Yojna, the government informed Parliament on Friday.
-
Trump Announces Upto 200% Tariffs On Generic Drugs, Move May Impact India
India is often called the "pharmacy of the world" as it supplies generic medicines to countries across the globe. In the US, Indian generic medicines make up nearly 40 per cent by volume.
-
Why Are Indians Quitting Weight-Loss Drugs Despite Lower Prices?
Generic GLP-1 drugs are cheaper than ever, but many Indians aren't staying on treatment. Here's why doctors say retention, not affordability, is the real challenge.
-
India Needs To Strengthen Its Position As Global Pharmaceutical And Innovation Hub: NITI Aayog
Global pharmaceutical and API import demand is valued at approximately $1.3 trillion, including $261.2 billion in Active Pharmaceutical Ingredients (APIs) for 2025.
-
Jan Aushadhi Kendras Expand Across India From 84 In 2014 To More Than 19,200 In 2026
New Delhi, June 17 (IANS) From around 84 functional Jan Aushadhi Kendras in 2014, the network has grown to more than 19,200 Kendras across the country in 2026, making quality generic medicines accessible at affordable prices to millions of citizens, the government said on Wednesday.
-
Drug Regulator Tightens Watch On GLP-1 Weight-Loss Drugs, Issues Notice
The Central Drugs Standard Control Organization, along with state regulators, has initiated targeted enforcement measures to curb malpractices and ensure ethical pharmaceutical practices in the supply chain.
-
Drug Regulator Tightens Watch On GLP-1 Weight-Loss Drugs, Issues Notice
The Central Drugs Standard Control Organization, along with state regulators, has initiated targeted enforcement measures to curb malpractices and ensure ethical pharmaceutical practices in the supply chain.
-
Safety Checks For New Generic Weight-Loss Drugs To Be Increased: Government
New Delhi, March 24 (IANS) Amid serious concerns over recent introduction of multiple generic variants of GLP-1 based weight loss drugs in the Indian market, the government on Tuesday said it has intensified regulatory surveillance against the drug’s
-
Safety Checks For New Generic Weight-Loss Drugs To Be Increased: Government
New Delhi, March 24 (IANS) Amid serious concerns over recent introduction of multiple generic variants of GLP-1 based weight loss drugs in the Indian market, the government on Tuesday said it has intensified regulatory surveillance against the drug’s
-
Ozempic Copycats Arrive: From Rs 11,000 To Rs 3,000, How Patent Expiry Is Reshaping Diabetes Treatment
With patent protection ending, Indian companies have moved quickly to introduce lower-cost versions with monthly therapy expected at around Rs 3,000 to Rs 4,000 for initial doses
-
Ozempic Copycats Arrive: From Rs 11,000 To Rs 3,000, How Patent Expiry Is Reshaping Diabetes Treatment
With patent protection ending, Indian companies have moved quickly to introduce lower-cost versions with monthly therapy expected at around Rs 3,000 to Rs 4,000 for initial doses
-
Weight Loss Injection For ₹900? Three Pharma Firms Launch Affordable Semaglutide, Check Prices
Indian pharmaceutical companies have launched affordable versions of semaglutide injections following a patent expiry, significantly lowering costs for diabetes and weight management treatment and improving access for millions of patients.
-
Indian Pharma Giants Launch Low-Cost Generic Semaglutide Injections For Diabetes, Weight Management
New Delhi, March 21 (IANS) Three Indian pharmaceutical companies have launched generic versions of semaglutide injections, after the drug’s patent expired, offering lower‑cost options for patients managing Type 2 diabetes and obesity.
-
Indian Pharma Giants Launch Low-Cost Generic Semaglutide Injections For Diabetes, Weight Management
New Delhi, March 21 (IANS) Three Indian pharmaceutical companies have launched generic versions of semaglutide injections, after the drug’s patent expired, offering lower‑cost options for patients managing Type 2 diabetes and obesity.
-
India Supplies 30% Of Global Generic Drugs: What You Should Know
India supplies nearly thirty percent of the worlds generic medicines and aims to boost domestic use to reduce patients out-of-pocket costs.
-
Jan Aushadhi Scheme Saves Citizens Rs 45,000 Crore On Medicines In 12 Years: Govt
A total of 20,149 Jan Aushadhi Kendras have been opened nationwide and estimated savings of about Rs 45,000 crore have accrued to citizens from the Pradhan Mantri Bhartiya Janaushadhi Yojna, the government informed Parliament on Friday.
-
Trump Announces Upto 200% Tariffs On Generic Drugs, Move May Impact India
India is often called the "pharmacy of the world" as it supplies generic medicines to countries across the globe. In the US, Indian generic medicines make up nearly 40 per cent by volume.
-
Why Are Indians Quitting Weight-Loss Drugs Despite Lower Prices?
Generic GLP-1 drugs are cheaper than ever, but many Indians aren't staying on treatment. Here's why doctors say retention, not affordability, is the real challenge.
-
India Needs To Strengthen Its Position As Global Pharmaceutical And Innovation Hub: NITI Aayog
Global pharmaceutical and API import demand is valued at approximately $1.3 trillion, including $261.2 billion in Active Pharmaceutical Ingredients (APIs) for 2025.
-
Jan Aushadhi Kendras Expand Across India From 84 In 2014 To More Than 19,200 In 2026
New Delhi, June 17 (IANS) From around 84 functional Jan Aushadhi Kendras in 2014, the network has grown to more than 19,200 Kendras across the country in 2026, making quality generic medicines accessible at affordable prices to millions of citizens, the government said on Wednesday.
-
Drug Regulator Tightens Watch On GLP-1 Weight-Loss Drugs, Issues Notice
The Central Drugs Standard Control Organization, along with state regulators, has initiated targeted enforcement measures to curb malpractices and ensure ethical pharmaceutical practices in the supply chain.
-
Drug Regulator Tightens Watch On GLP-1 Weight-Loss Drugs, Issues Notice
The Central Drugs Standard Control Organization, along with state regulators, has initiated targeted enforcement measures to curb malpractices and ensure ethical pharmaceutical practices in the supply chain.
-
Safety Checks For New Generic Weight-Loss Drugs To Be Increased: Government
New Delhi, March 24 (IANS) Amid serious concerns over recent introduction of multiple generic variants of GLP-1 based weight loss drugs in the Indian market, the government on Tuesday said it has intensified regulatory surveillance against the drug’s
-
Safety Checks For New Generic Weight-Loss Drugs To Be Increased: Government
New Delhi, March 24 (IANS) Amid serious concerns over recent introduction of multiple generic variants of GLP-1 based weight loss drugs in the Indian market, the government on Tuesday said it has intensified regulatory surveillance against the drug’s
-
Ozempic Copycats Arrive: From Rs 11,000 To Rs 3,000, How Patent Expiry Is Reshaping Diabetes Treatment
With patent protection ending, Indian companies have moved quickly to introduce lower-cost versions with monthly therapy expected at around Rs 3,000 to Rs 4,000 for initial doses
-
Ozempic Copycats Arrive: From Rs 11,000 To Rs 3,000, How Patent Expiry Is Reshaping Diabetes Treatment
With patent protection ending, Indian companies have moved quickly to introduce lower-cost versions with monthly therapy expected at around Rs 3,000 to Rs 4,000 for initial doses
-
Weight Loss Injection For ₹900? Three Pharma Firms Launch Affordable Semaglutide, Check Prices
Indian pharmaceutical companies have launched affordable versions of semaglutide injections following a patent expiry, significantly lowering costs for diabetes and weight management treatment and improving access for millions of patients.
-
Indian Pharma Giants Launch Low-Cost Generic Semaglutide Injections For Diabetes, Weight Management
New Delhi, March 21 (IANS) Three Indian pharmaceutical companies have launched generic versions of semaglutide injections, after the drug’s patent expired, offering lower‑cost options for patients managing Type 2 diabetes and obesity.
-
Indian Pharma Giants Launch Low-Cost Generic Semaglutide Injections For Diabetes, Weight Management
New Delhi, March 21 (IANS) Three Indian pharmaceutical companies have launched generic versions of semaglutide injections, after the drug’s patent expired, offering lower‑cost options for patients managing Type 2 diabetes and obesity.
